Emerging Targets in the Management of Schizophrenia: The Potential of TAAR1 Agonists

FACULTY

Leslie Citrome, MD, MPH
Clinical Professor of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, NY

Amber Hoberg, NP
Founder, CEO, and Psychiatric Mental Health Nurse Practitioner  
Enlighten Health Care, LLC
San Antonio, TX

Rakesh Jain, MD, MPH
Private Practice  
Clinical Professor
Department of Psychiatry 
Texas Tech University Health Sciences Center
School of Medicine - Permian Basin
Midland, TX

PROVIDER STATEMENT

Provided by HMP Education, an HMP Global Company.

INTENDED LEARNERS

This activity is designed for psychiatrists, primary care physicians, psychologists, nurse practitioners, physician assistants, psychiatric nurses, and other healthcare professionals who seek to improve the care of patients with mental health disorders.

LEARNING OBJECTIVES

After participating in this activity, learners should be better able to:

• Describe the limitations and barriers associated with the use of antipsychotics for schizophrenia whose MOA centers on dopamine D2 binding, including a discussion surrounding antipsychotic nomenclature
• Evaluate the mechanism of action and safety/efficacy data associated with TAAR1 agonism in the management of schizophrenia
• Summarize the potential clinical implications for TAAR1 agonists in the management of schizophrenia and how to identify/educate patients who might benefit from these novel therapies

ACTIVITY OVERVIEW

This on-demand webcast is available with synchronized slides and video/audio. 

To be eligible for documentation of credit for each session attended, learners must participate in the activity and complete the educational activity evaluation. Participants who complete the evaluation online within active dates of the training will receive documentation of credit. Your certificate may not load if you are accessing it from a smartphone, or settings of your browser do not allow for a new tab/window to open.  

Once a certificate has been claimed, physicians and pharmacists may elect for credits to be submitted on their behalf to their boards via additional fields that will appear within the Claim Certificate page. Credits must be submitted through this process to be reported to the American Board of Surgery and the National Association of Boards of Pharmacy. 

Release Date: December 21, 2023 
Expiration Date: December 21, 2024
Estimated Time to Complete: .5 hour

There is no fee associated with this activity.

HARDWARE/SOFTWARE REQUIREMENTS

The activity is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. 

CONTINUING EDUCATION

In support of improving patient care, HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Note: This statement is not an indication of approved credits. Please see below for full accreditation details, including credit types and totals, for this activity.

PHYSICIANS

HMP Education designates this internet enduring activity for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACISTS

This internet enduring, knowledge-based activity (Universal Activity Number: JA0006201-0000-23-215-H01-P) has been approved for a maximum of .5 contact hour (.05 CEUs).

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in the CPE Monitor system. Following ACPE Policy, HMP Education must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity. HMP Education is not able to report your claimed credit after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.

NURSES

This continuing nursing education internet enduring activity awards .5 contact hour.

NURSE PRACTITIONERS

American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit^TM from organizations accredited by the ACCME.

PHYSICIAN ASSOCIATES / ASSISTANTS

HMP Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for .5 AAPA Category 1 credit. Approval is valid until December 21, 2024. PAs should only claim credit commensurate with the extent of their participation.
 

INTERNATIONAL RECOGNITION

The following Countries, Regions, and Accrediting Bodies accept, or have reciprocity or mutual recognition of credits with the AMA/ACCME. Please contact the accrediting body to find out more information on submitting or converting your credits.

• Bavarian Chamber of Physicians (Germany)
• Bulgarian Union of Scientific Medical Societies (Bulgaria)
• Canadian Medical Association (Canada)
• Canadian Nurses Association (Canada)
• EBAC® (European Board for Accreditation of Continuing Education for Health Professionals)
• Federation of Royal Colleges of Physicians (UK)
• French National Medical Council (France)
• Italian Federation of Scientific Medical Societies (Italy)
• National CME Commission of the Italian Ministry of Health (Italy)
• Spanish Accreditation Council for CME (Spain)
• UEMS-EACCME® (European Union of Medical Specialists)

USE OF PROPRIETARY NAMES

This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.

UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of HMP Education.

DISCLAIMERS

The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a provider-patient relationship. Medical advice of any nature should be sought from an individual’s own provider.

The opinions expressed in this educational activity are those of the faculty and are not attributable to HMP Global or any of its subsidiaries or affiliates. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

HMP Education is an independent provider of continuing medical education. HMP Education has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

In accordance with our disclosure policies, HMP Education is committed to ensuring balance, independence, objectivity, and scientific rigor for all accredited continuing education. These policies include assigning relevance to, and mitigating, all perceived or real relevant financial relationship (conflicts of interest) between any individual with control over the content and any ineligible company (commercial interest) as defined by the ACCME and CPME.

Any individual with control over accredited content, including planner, faculty, and reviewer, is required to globally disclose:

1. Individual relationship(s) or lack thereof, and its nature, with any/all ineligible company, and;
2. Any investigational, off-label, or non-FDA approved content or discussion

HMP Education has reviewed these disclosures, assigned relevance based on the relationship and scope of content, and identified those with the potential to compromise the goals and educational integrity of the education. Relevant relationships, or lack thereof, are shared with the learner.

Education has been independently peer-reviewed to validate content, mitigate identified financial relationships (conflicts of interest), and ensure:

1. All recommendations involving clinical medicine is based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients.
2. All scientific research referred to, reported, or used in accredited continuing education in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection, and analysis.
3. Content is appropriate, fair and balanced, unbiased, referenced, and non-promotional.

All relevant financial relationships have been mitigated.

FACULTY

The faculty has reported the following:

Dr. Citrome: Consultant – AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Marvin, Merck, Mitsubishi-Tanabe Pharma, Neurocrine, Neurelis, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sunovion, Supernus, Teva, University of Arizona, Vanda, and one-off ad hoc consulting for individuals/entities conducting marketing, commercial, or scientific scoping research; Speaker– AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, Teva, and CME activities organized by medical education companies such as Medscape, NACCME, NEI, Vindico, and Universities and Professional Organizations/Societies; Stocks (small number of shares of common stock) – Bristol-Myers Squibb, Eli Lilly, J & J, Merck, Pfizer purchased > 10 years ago, stock options: Reviva; Royalties/Publishing Income – Taylor & Francis (Editor-in-Chief, Current Medical Research and Opinion, 2022-date), Wiley (Editor-in-Chief, International Journal of Clinical Practice, through end 2019), UpToDate (reviewer), Springer Healthcare (book), Elsevier (Topic Editor, Psychiatry, Clinical Therapeutics)

Ms. Hoberg: as disclosed no relevant financial relationship with any ineligible company (commercial interest).

Dr. Jain: Advisory Board—Adamas, Alkermes, Corium, Eisai, Indivior, Intra-Cellular Therapies, Ironshore Pharmaceuticals, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer, Shire, Sunovion, Supernus, Takeda, Teva, Tris Pharmaceuticals; Advisory Board (spouse)—Otsuka; Consultant—AbbVie (Allergan), Acadia, Adamas, Alfasigma USA, Inc., Axsome, Corium, Cingulate Therapeutics,  Eisai, Evidera, Impel NeuroPharma, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Osmotica, Otsuka, Pamlab, Pfizer, Sage Therapeutics, Shire, Sunovion, Supernus, Takeda, Teva; Consultant (spouse)—Lilly, Otsuka, Pamlab, Sunovion; Grant/Research Support— AbbVie (Allergan), Lilly, Lundbeck, Otsuka, Pfizer, Shire, Takeda; Speakers Bureau—AbbVie (Allergan), Alkermes, Axsome, Corium, Eisai, Indivior, Intracellular Therapies, Ironshore Pharmaceuticals, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine, Otsuka, Pamlab, Pfizer, Shire, Sunovion, Takeda, Teva, Tris Pharmaceuticals; Speakers Bureau (spouse)—Lilly.

CLINICAL REVIEWER

Craig Chepke, MD, DFAPA
Medical Director
Excel Psychiatric Associates
Huntersville, NC

Dr. Chepke: Advisory Board—Abbvie, Acadia, Alkermes, Corium, Eisai, Idorsia, Intracellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Takeda, Teva; Advisory Board (Spouse)—Otsuka; Consultant—AbbVie, Alkermes, Corium, Eisai, Intracellular, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Takeda, Teva; Grant Research/Support—Acadia, Axsome, Biohaven, Harmony, Neurocrine, Teva; Speaker’s Bureau—AbbVie, Acadia, Alkermes, Eisai, Intracellular, Ironshore, Janssen, Jazz, Lundbeck, Merck, Neurocrine, Noven, Otsuka, Sunovion, Takeda, Teva.

PLANNING COMMITTEE

Susie Seaman, NP, MSN, CWCN, CWS (nurse planner)
Wound Clinic, Family Health Centers of San Diego
San Diego, California

Ms. Seaman has disclosed no relevant financial relationship with any ineligible company (commercial interest).

HMP Education planners and staff include Meaghan Benci, Kristin Ciszeski; Samantha Joy; Randy Robbin; Lacey Schmeidler and Andrea Zimmerman, EdD.

No HMP Education planner or staff has disclosed a relevant financial relationship with any ineligible company (commercial interest).

ADA STATEMENT

HMP Education complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity needs accommodation(s), please submit a request to contact the support team. 

PRIVACY POLICY

HMP Education protects the privacy of personal and other information regarding participants, educational partners, and joint providers. HMP Education and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. HMP Education maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2024 by HMP Education. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from HMP Education.

COMMERCIAL SUPPORT

Supported by independent educational grants from Sumitomo Pharma America and Otsuka America Pharmaceutical, Inc.

CONTACT US 

For immediate assistance, please explore our HMP Education Help Center or chat with our Virtual CE Assistant who can answer most common questions related to claiming credits and the HMP Education website. If you have a question or grievance that cannot be answered by our Virtual CE assistant and Help Center, please submit a request to contact the support team. Our accreditation and compliance team will respond to your inquiry within 1 business day.